{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:24:01Z","timestamp":1791908641905,"version":"4.3.4"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Adelphi Real World"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There is limited real-world evidence on how increasing use of treatment intensification in metastatic castration-sensitive prostate cancer (mCSPC) has influenced treatment decisions in metastatic castration-resistant prostate cancer (mCRPC). The study objective was to evaluate the impact of novel hormonal therapy (NHT) and docetaxel use in mCSPC on first-line treatment patterns among patients with mCRPC in 5 European countries and the United States (US).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Physician-reported data on patients with mCRPC from the Adelphi Prostate Cancer Disease Specific Program were descriptively analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 215 physicians provided data on 722 patients with mCRPC. Across 5 European countries and the US, 65% and 75% of patients, respectively, received NHT, and 28% and 9% of patients, respectively, received taxane chemotherapy as first-line mCRPC treatment. In Europe, patients who had received NHT in mCSPC (n = 76) mostly received taxane chemotherapy in mCRPC (55%). Patients who had received taxane chemotherapy, or who did not receive taxane chemotherapy or NHT in mCSPC (n = 98 and 434, respectively) mostly received NHT in mCRPC (62% and 73%, respectively). In the US, patients who had received NHT, taxane chemotherapy, or neither in mCSPC (n = 32, 12, and 72, respectively) mostly received NHT in mCRPC (53%, 83%, and 83%, respectively). Two patients in Europe were rechallenged with the same NHT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These findings suggest that physicians consider mCSPC treatment history when making first-line treatment decisions in mCRPC. Further studies are needed to better understand optimal treatment sequencing, especially as new treatments emerge.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad046","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T15:05:10Z","timestamp":1680620710000},"page":"e737-e747","source":"Crossref","is-referenced-by-count":22,"title":["Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-2951","authenticated-orcid":false,"given":"Pedro C","family":"Barata","sequence":"first","affiliation":[{"name":"Department of Hematology Oncology, University Hospitals Seidman Cancer Center , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Leith","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Adelphi Real World , Bollington , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Ribbands","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Adelphi Real World , Bollington , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Adelphi Real World , Bollington , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Last","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Formerly of Adelphi Real World , Bollington , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhakti","family":"Arondekar","sequence":"additional","affiliation":[{"name":"Global Value and Evidence, Oncology, Pfizer Inc. , Collegeville, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Ivanova","sequence":"additional","affiliation":[{"name":"Global Value and Evidence, Oncology, Pfizer Inc. , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Niyazov","sequence":"additional","affiliation":[{"name":"Global Value and Evidence, Oncology, Pfizer Inc. , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"2023090805131578000_CIT0001","author":"U.S. Food & Drug"},{"key":"2023090805131578000_CIT0002","author":"European Medicines Agency"},{"key":"2023090805131578000_CIT0003","author":"European Medicines Agency"},{"key":"2023090805131578000_CIT0004","author":"European Medicines Agency"},{"key":"2023090805131578000_CIT0005","author":"European Medicines Agency"},{"key":"2023090805131578000_CIT0006","author":"European Medicines Agency"},{"key":"2023090805131578000_CIT0007","author":"European Medicines Agency"},{"key":"2023090805131578000_CIT0008","author":"European Medicines Agency"},{"key":"2023090805131578000_CIT0009","author":"European Medicines Agency"},{"issue":"4","key":"2023090805131578000_CIT0010","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40291-022-00594-2","article-title":"Lutetium Lu 177 vipivotide tetraxetan: first approval","volume":"26","author":"Keam","year":"2022","journal-title":"Mol Diagn Ther"},{"key":"2023090805131578000_CIT0011","author":"U.S. Food & Drug"},{"key":"2023090805131578000_CIT0012","author":"U.S. Food & Drug"},{"key":"2023090805131578000_CIT0013","author":"U.S. Food & Drug"},{"key":"2023090805131578000_CIT0014","author":"U.S. Food & Drug"},{"key":"2023090805131578000_CIT0015","author":"U.S. Food & Drug"},{"key":"2023090805131578000_CIT0016","author":"U.S. Food & Drug"},{"issue":"22","key":"2023090805131578000_CIT0017","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"32","key":"2023090805131578000_CIT0018","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"2023090805131578000_CIT0019","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"2023090805131578000_CIT0020","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 Study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2023090805131578000_CIT0021","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"2023090805131578000_CIT0022","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"20","key":"2023090805131578000_CIT0023","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"32","key":"2023090805131578000_CIT0024","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol."},{"issue":"10024","key":"2023090805131578000_CIT0025","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet."},{"issue":"11","key":"2023090805131578000_CIT0026","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol."},{"key":"2023090805131578000_CIT0027","author":"European Medicines Agency"},{"key":"2023090805131578000_CIT0028","author":"European Medicines Agency"},{"key":"2023090805131578000_CIT0029","author":"European Medicines Agency"},{"key":"2023090805131578000_CIT0030","author":"Janssen Biotech Inc"},{"key":"2023090805131578000_CIT0031","author":"Astellas Pharma US"},{"issue":"23","key":"2023090805131578000_CIT0032","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1002\/cam4.4372","article-title":"Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration","volume":"10","author":"Freedland","year":"2021","journal-title":"Cancer Med"},{"issue":"6","key":"2023090805131578000_CIT0033","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1097\/JU.0000000000002121","article-title":"Management of patients with metastatic castration-sensitive prostate cancer in the real-world setting in the United States","volume":"206","author":"Ryan","year":"2021","journal-title":"J Urol"},{"issue":"19","key":"2023090805131578000_CIT0034","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.3390\/cancers13194951","article-title":"Treatment pattern and outcomes with systemic therapy in men with metastatic prostate cancer in the real-world patients in the United States","volume":"13","author":"Swami","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2023090805131578000_CIT0035","doi-asserted-by":"crossref","first-page":"pkab082","DOI":"10.1093\/jncics\/pkab082","article-title":"Real-world use of \u00adandrogen-deprivation therapy: intensification among older Canadian men with de novo metastatic prostate cancer","volume":"5","author":"Wallis","year":"2021","journal-title":"JNCI Cancer Spectr"},{"issue":"15_suppl","key":"2023090805131578000_CIT0036","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1200\/JCO.2021.39.15_suppl.5072","article-title":"Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-\u00adsensitive prostate cancer (mCSPC) in a U.S. health insurance database","volume":"39","author":"Swami","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2023090805131578000_CIT0037","doi-asserted-by":"crossref","first-page":"S541","DOI":"10.1016\/j.annonc.2020.08.938","article-title":"679P Treatment patterns of metastatic castration-sensitive prostate cancer (mCSPC): a real-world evidence study","volume":"31","author":"Tagawa","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"2023090805131578000_CIT0038","doi-asserted-by":"crossref","first-page":"S650","DOI":"10.1016\/j.annonc.2021.08.1122","article-title":"609P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019","volume":"32","author":"Freedland","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"2023090805131578000_CIT0039","doi-asserted-by":"crossref","first-page":"S655","DOI":"10.1016\/j.annonc.2021.08.1129","article-title":"616P Real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-\u00adsensitive prostate cancer (mCSPC): a Medicare database analysis","volume":"32","author":"George","year":"2021","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"2023090805131578000_CIT0040","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2021.39.15_suppl.5074","article-title":"Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings","volume":"39","author":"George","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2023090805131578000_CIT0041","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.1200\/JCO.2021.39.15_suppl.5073","article-title":"Real-world utilization of advanced therapies and racial disparity among patients with metastatic castration-sensitive prostate cancer (mCSPC): a Medicare database analysis","volume":"39","author":"Freedland","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"2023090805131578000_CIT0042","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1200\/JCO.2022.40.6_suppl.183","article-title":"Underutilization of standard of care (SOC) treatment intensification in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by specialty","volume":"40","author":"Swami","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"2023090805131578000_CIT0043","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1200\/JCO.2022.40.6_suppl.086","article-title":"Evolving real-world patterns of practice in metastatic castration-sensitive prostate cancer (mCSPC): the genitourinary research consortium (GURC) national multicenter cohort study","volume":"40","author":"Yip","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"2023090805131578000_CIT0044","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/JU.0000000000001376","article-title":"Advanced prostate cancer: AUA\/ASTRO\/SUO guideline PART II","volume":"205","author":"Lowrance","year":"2021","journal-title":"J Urol"},{"key":"2023090805131578000_CIT0045","author":"Mottet"},{"issue":"9","key":"2023090805131578000_CIT0046","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"issue":"10","key":"2023090805131578000_CIT0047","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J Clin Investig"},{"issue":"12","key":"2023090805131578000_CIT0048","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"2023090805131578000_CIT0049","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/j.clgc.2019.09.006","article-title":"The effect of treatment sequence on overall survival for men with metastatic castration-\u00adresistant prostate cancer: a multicenter retrospective study","volume":"18","author":"Okita","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"2023090805131578000_CIT0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/pros.23246","article-title":"Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study","volume":"77","author":"Maughan","year":"2017","journal-title":"Prostate"},{"issue":"11","key":"2023090805131578000_CIT0051","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: disease-specific programmes\u2014a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"2023090805131578000_CIT0052","doi-asserted-by":"crossref","first-page":"e010352","DOI":"10.1136\/bmjopen-2015-010352","article-title":"Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific \u00adprogramme","volume":"6","author":"Babineaux","year":"2016","journal-title":"BMJ Open"},{"key":"2023090805131578000_CIT0053","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","volume":"9","author":"Higgins","year":"2016","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2023090805131578000_CIT0054","author":"ECOG-ACRIN Cancer Research Group"},{"key":"2023090805131578000_CIT0055","author":"European Pharmaceutical Market Research Association (EphMRA)"},{"key":"2023090805131578000_CIT0056","author":"US Department of Health and Human Services"},{"key":"2023090805131578000_CIT0057","author":"Health Information Technology (HITECH)"},{"issue":"4","key":"2023090805131578000_CIT0058","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"2023090805131578000_CIT0059","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"issue":"1","key":"2023090805131578000_CIT0060","doi-asserted-by":"crossref","first-page":"1.e1","DOI":"10.1016\/j.urolonc.2019.09.027","article-title":"Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer","volume":"38","author":"Halwani","year":"2020","journal-title":"Urol Oncol"},{"key":"2023090805131578000_CIT0061","first-page":"1","article-title":"Metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: treatment patterns from the PROXIMA prospective registry","volume":"4","author":"Akaza","year":"2018","journal-title":"J Glob Oncol"},{"issue":"5","key":"2023090805131578000_CIT0062","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1177\/10781552211015767","article-title":"Global changes to the chemotherapy service during the covid-19 pandemic","volume":"27","author":"Chow","year":"2021","journal-title":"J Oncol Pharm Pract."},{"issue":"16_suppl","key":"2023090805131578000_CIT0063","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1200\/JCO.2022.40.16_suppl.5065","article-title":"Reasons for oncologist and urologist treatment choice in metastatic castration-\u00adsensitive prostate cancer (mCSPC): a physician survey linked to patient chart reviews in the United States","volume":"40","author":"Freedland","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/9\/e737\/51436945\/oyad046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/9\/e737\/51436945\/oyad046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T05:13:40Z","timestamp":1694150020000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/9\/e737\/7103239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":63,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,4,4]]},"published-print":{"date-parts":[[2023,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad046","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,4,4]]}}}